Targeting oncogenic BRAF and aberrant MAP kinase activation in the treatment of cutaneous melanoma
Cet article passe en revue les perspectives offertes par les travaux récents sur la voie de signalisation MAPK pour développer de nouveaux traitements des patients atteints d'un mélanome présentant un gène BRAF muté
BRAF and MEK inhibitors, alone or in combination, are highly active in the 40% of patients with BRAF mutant metastatic melanoma. Despite this activity resistance often develops in patients treated with these agents. This review summarises the biology of the mitogen activated protein kinase (MAPK) pathway, with particular reference to the effects of BRAF and MEK inhibitors in BRAF mutant melanoma. The clinical and molecular predictors of response and mechanisms of resistance are discussed in detail along with the biological rationale and evidence for future treatment strategies in both MAPK inhibitor naïve and resistant BRAF mutant melanoma.
http://www.sciencedirect.com/science/article/pii/S1040842815300366